Earlier this year we published a white paper on the new commercial realities and their implications for Life Sciences companies.

George Osborne’s first Budget as chancellor has had a mixed reception from the pharma and biotech sectors. The BioIndustry Association …
More and more doctors in the US are refusing to see pharma companies’ sales representatives, according to new research. The …
Action Pharma’s Torben Jung Laursen explores the new challenges facing pharma-biotech partnering as a result of the economic downturn.In today’s …
The Merck and Schering-Plough merger creates a new industry giant to challenge Pfizer in terms of its scale and annual …
Pharma has always been a highly profitable industry, and has historically been among the best performing industrial sectors in terms …
Biotech leaders in the UK say the cash-stricken industry has reached ‘breaking point’, and have made an unprecedented plea for …
A review of the NHS in 2008 NHS-pharma collaborations come of ageIn January, new guidelines were agreed to help NHS …
Patient power proves decisive in battle for accessSocial networking helped a new breed of informed patient advocates win the …
The relationship between doctors and the pharmaceutical industry has attracted considerable criticism in the past five years. Scepticism has risen, …
The 2008 edition of the ABPI Code of Practice came into force on 1 July and the industry is fairly …
In the headlong race for global domination, pharma companies are in the process of flattening their hierarchies, slashing bureaucracy, streamlining …